PTHS and CHRO Related Headlines
Go Back- Pelthos Therapeutics Launches ZELSUVMI™ (berdazimer) Topical Gel 10.3%, the First and Only FDA-Approved At-Home Treatment for Molluscum Contagiosum
- Pelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private Placement
PTHS and CHRO Related Press Releases
Go Back- Pelthos Therapeutics Launches ZELSUVMI™ (berdazimer) Topical Gel 10.3%, the First and Only FDA-Approved At-Home Treatment for Molluscum Contagiosum
- Pelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private Placement
